Biological mechanisms of dopamine D2-like receptor agonist therapy in diabetes
Open Access
- 20 January 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1532414
Abstract
A recent case report by Sahota and colleagues has provided new insights into treatment of dysglycemia via dopamine (DA) receptor stimulation in the setting of autoimmune diabetes [1].Briefly, a patient with autoimmune diabetes was diagnosed with a pituitary prolactinoma, resulting in treatment with cabergoline, an agonist of DA D2-like receptors, alongside preexisting diabetes medications. Over time, the patient was switched to cabergoline monotherapy which reversed his insulin requirement. This led to significantly improved glycemic control and a revised diagnosis of latent autoimmune diabetes of adults (LADA). Ultimately, however, the patient was restarted on insulin therapy in the setting of progressively increased blood glucose.Patients with LADA often achieve adequate glycemic control soon after the initiation of antihyperglycemic treatment, including non-insulin agents [2]. Consistent with this, recent studies in LADA patients with non-insulin agents like dipeptidyl peptidase 4 inhibitors (e.g., saxagliptin), or glucagon-like peptide 1 receptor agonists (e.g., dulaglutide) showed improved glycemic control for months and delayed progression to insulin requirement [2; 3; 4; 5]. Importantly, in contrast to the more commonly used drug classes above, this case represents the first description of DA receptor agonist monotherapy for autoimmune diabetes [1]. These findings have raised important questions concerning the biological mechanisms by which D2-like receptor agonists can effectively treat dysglycemia, particularly in the setting of diabetes.D2-like receptor agonists such as cabergoline and bromocriptine have been used for decades to control CNS prolactinoma size and secretion given their expression of the DA D2 receptor (D2R) [6]. There is much evidence that these agonists are associated with improved glycemic control [7]. Moreover, bromocriptine was approved by the United States Food & Drug Administration as a novel treatment for dysglycemia in type 2 diabetes mellitus (T2DM) [8; 9].While mechanisms by which D2-like receptor agonists improve glycemic control have remained unclear, most attention has been devoted to these drugs' actions on neuroendocrine targets within the central nervous system (CNS) [8].Sahota et al. suggested that drug-induced reduction of pathological prolactin levels led to the patient's metabolic improvements [1]. CNS D2R agonism via cabergoline therapy could therefore modify prolactin-induced disruptions in lipid and glucose metabolism in insulinresponsive tissues including adipose tissue and skeletal muscle [1; 10; 11]. These prolactin reductions also likely contributed to improved testosterone levels, which in turn reversed the patient's hypogonadism. This is consistent with evidence showing that testosterone restoration contributes to significant weight loss as well as improved insulin resistance and overall glycemic control [12; 13]. Cabergoline-induced normalization of prolactin may therefore lead to restored total and free testosterone levels to improve glycemic control via a wide range of mechanisms including via reductions in inflammation and weight gain -factors that further drive insulin resistance [11; 14]. Moreover, D2R is also expressed in the hypothalamus and is implicated in centrally-mediated metabolic regulation, including through control over satiety [15; 16].Therefore, it is possible that D2R agonists may improve glycemic control via these CNS pathways, in addition to its actions in the pituitary (Figure 1A).Though CNS DA receptor agonism was proposed by Sahota et al. as a primary driver of improved glycemic control [1], additional factors likely play key roles. A leading determinant of improved glucose control is the "honeymoon" effect where patients present with temporary remission after symptomatic onset. The honeymoon period in LADA typically lasts weeks to months and may reflect reduced stress on remaining islet beta-cells [17; 18; 19]. Body weight loss similarly improves glycemic control, which in turn lowers cell stress to help preserve beta-cell function (e.g., insulin synthesis and release) [20].In addition to CNS targets, we posit that the ability of D2-like receptor agonists to effectively treat dysglycemia in diabetes is at least in part via their actions on metabolically relevant peripheral targets including the endocrine pancreas. We and others demonstrated that pancreatic islet cells express D2-like receptors [21; 22; 23; 24; 25; 26]. Moreover, alpha-cells and beta-cells produce their own DA which signals locally via D2-like receptors as an autocrine/paracrine negative modulator of insulin and glucagon secretion [21; 22; 26; 27]. More recently, we found that bromocriptine acts directly on peripheral D2R to inhibit islet insulin and glucagon secretion [28]. It is possible that D2-like receptor agonist inhibition of glucose-stimulated insulin secretion (GSIS) therefore leads to "beta-cell rest." Lowering excessive insulin release may reduce cytotoxic beta-cell stress and re-sensitize insulin-resistant tissues like skeletal muscle, adipose tissue, and liver to improve dysglycemia [26]. Interestingly, besides DA receptors, betacells also express inhibitory adrenergic receptors including alpha2A adrenergic receptors which can similarly be stimulated by local DA or D2-like receptor agonists like bromocriptine [22; 28; 29].This results in further inhibition of GSIS [22; 28; 29]. Likewise, diminishing alpha-cell glucagon secretion via D2R agonism may concurrently lower hyperglycemia and improve both insulin resistance and overall glycemic control [26] (Figure 1B).D2-like receptors are expressed in adipose tissue [30; 31]. Increasing evidence suggests that dopaminergic signaling in adipocytes modulates expression of adipokines including leptin [32; 33; 34]. Consistent with this, recent work showed that D2R expression was upregulated in human subcutaneous adipose tissue in response to hyperglycemia and T2DM [34]. The DA D4...Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases
- U.S. Department of War
This publication has 40 references indexed in Scilit:
- Subcutaneous adipose tissue dopamine D2 receptor is increased in prediabetes and T2DEndocrine, 2023
- Dual pancreatic adrenergic and dopaminergic signaling as a therapeutic target of bromocriptineiScience, 2022
- Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in type 2 diabetesMolecular Metabolism, 2021
- New roles for dopamine D2 and D3 receptors in pancreatic beta cell insulin secretionMolecular Psychiatry, 2019
- The Leptin, Dopamine and Serotonin Receptors in Hypothalamic POMC-Neurons of Normal and Obese RodentsNeurochemical Research, 2018
- Concise Review: Cell-Based Therapies and Other Non-Traditional Approaches for Type 1 DiabetesStem Cells, 2016
- A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parametersPrimary Care Diabetes, 2016
- Molecular pathophysiology of metabolic effects of antipsychotic medicationsTrends in Endocrinology & Metabolism, 2014
- The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the α2-adrenergic receptors in beta cellsBiochemical Pharmacology, 2010
- Dopamine inhibits cytokine release and expression of tyrosine kinases, Lck and Fyn in activated T cellsInternational Immunopharmacology, 2003